Programme-at-a-glance of Industry satellite symposia and workshop activities

		Wednesday 16 June 2010			Thursday 17 June 2010					Friday 18 June 2010
	ROOM	14.00 - 15.30			12.30 - 13.30 (INTERSESSION)		18.00 - 19.30 (EVENING SESSION)			12.30 - 13.30 (INTERSESSION)		18.00 - 19.30 (EVENING SESSION)
	AMAZON (Function Hall A)				ISS	Servier International: Comprehensive risk management in hypertension: evidence from recent ...	ISS	Daiichi Sankyo Company Ltd: Hypertension management, 2010: How to optimize treatment		ISS	Servier International: Trimetazidine MR: management of ischemic heart disease
	MEKONG (Function Hall B)	ISS	Servier International: Ivabradine: revisiting the management of CAD patients		ISS	Pfizer Inc.: Partnering in Smoking Cessation - a remaining issue for cardiologists
	TIGRIS (Function Hall C)				ISS	MSD: Comprehensive lipid management: the new paradigm for optimal cardiovascular risk reduction				ISS	Boehringer Ingelheim: Reduction of myocardial infarction and stroke in high-risk patients with ...
	YANGTZE (Ballroom B)				ISS	Boehringer Ingelheim: Stroke prevention in atrial fibrillation - implications of dabigatran ...				ISS	sanofi-aventis: A new skyline in the management of atrial fibrillation: reducing cardiovascular ...
	NILE (Ballroom C)				ISS	Novartis Pharma AG: Exploring New Horizons in Hypertension Management: What can Direct Renin ...				ISS	Novartis Pharma AG: Contemporary Approaches to the Management of Hypertension and Cardiovascular ...
	DANUBE (301 A & B)						NCSS	International Cardiology Forum: Anticoagulant therapy in ACS: Defining the State of the Art		NCSS	Italian Heart Foundation: High Risk Population: Focus on CHD
	LENA (302 A & B)						ISS	Siemens AG: New Developments in Cardiovascular Imaging		ISS	Unilever: Personalising cardiovascular risk for positive behaviour change
	THAMES (307 A & B)				ISS	Merck Serono, an Affiliate of Merck KGaA: Role of BBs in the management of HTN - Asian perspective				ISS	Abbott Vascular: Women and Heart disease: Gender differences in Revascularization
	RIO GRANDE (306 A & B)						ISS	Nature Reviews Cardiology: Promotion of cardiovascular health through early detection of signs ...		NCSS	R3i Foundation: Lipid-related residual vascular risk: The emergence of new preventive strategies
	VOLGA (309 A)				ISS	Bayer Schering Pharma: Reducing cardiovascular risk - perspectives for the future				ISS	Alere International: The clinical utility of cardiovascular biomarkers: innovative views across ...
	EUPHRATES (309 B)				ISS	GlaxoSmithKline: ACS Focus-Major Bleeding				ISS	MSD - Merck Sharp & Dohme (China) 3B _the largest real world outcomes study in China
	PARANA (311 A)				ISS	Quaker - a PepsiCo Company: Nutrition, Inflammation, and Cardiovascular Risk Reduction
	RHINE (311 B)				ISS	STORZ MEDICAL AG: Non-invasive Revascularisation by Cardiac Shock Wave Therapy (CSWT) ...
	INDUS (402 A & B)						IWS	Pfizer Inc. Smoking Cessation Policy Workshop: Leveraging media to promote cardiac health and quality medical services		IWS	Pfizer Inc.: Smoking Cessation: A Practical Partnership - Breaking down the walls in smoking ...
	MISSISSIPPI (Plenary Hall A)				ISS	AstraZeneca: New Developments in Antiplatelet therapy for ACS Management: Where do we stand today?
	YELLOW RIVER (Plenary Hall B)				ISS	Pfizer Pharmaceuticals Ltd. (China): Exploring Optimized CAD Treatment Strategy				ISS	Pfizer Pharmaceuticals Ltd. (China): Updates in Hypertension Management-From Guidelines to ...
	JORDAN (Auditorium)				ISS	Yiling Pharmaceutical Group Atherosclerosis Treatment	ISS	Solvay Pharmaceuticals is now Abbott: A Priority; Reducing the Residual Vascular Risk				ISS	Solvay Pharmaceuticals is now Abbott: Putting brain and heart in the frame - the eprosartan ...